Journal: Molecular Pain

Article Title: Znhit1 alleviates nitroglycerin-induced hyperalgesia in migraine mice via the inhibition of NOD-like receptor signaling pathway

doi: 10.1177/17448069251389420

Figure Lengend Snippet: Znhit1 facilitated 5-HT expression and reduced the expression of c-Fos and CGRP in NTG-induced mice. (a–b) ELISA was used to assess 5-HT (a) and CGRP (b) levels in plasma ( n = 10). (c) The level of NO in the serum was evaluated using the colorimetric method ( n = 10). (d–e) The c-Fos and CGRP levels were detected in the TNC tissues using western blot (d) and IF (e) assays ( n = 5). One-way analysis of variance followed by Tukey’s post hoc test was utilized to perform statistical analysis. 5-HT: 5-hydroxytryptamine; c-Fos: FBJ osteosarcoma oncogene; CGRP: calcitonin gene-related peptide; ELISA: enzyme-linked immunosorbent assay; IF: immunofluorescence; NO: nitric oxide; NTG: nitroglycerin; TNC: trigeminal nucleus caudalis; Znhit1: zinc finger HIT-type containing 1. ** p < 0.01 versus control group; ## p < 0.01 versus vector group.

Article Snippet: The plasma was used to analyze 5-hydroxytryptamine (5-HT) and CGRP levels using ST/5-HT ELISA Kit (D751013, Sangon) and Mouse Calcitonin Gene Related Peptide (CGRP) ELISA kit (CSB-EQ027706MO, Cusabio).

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Western Blot, Peptide ELISA, Immunofluorescence, Control, Plasmid Preparation

Journal: Molecular Pain

Article Title: Znhit1 alleviates nitroglycerin-induced hyperalgesia in migraine mice via the inhibition of NOD-like receptor signaling pathway

doi: 10.1177/17448069251389420

Figure Lengend Snippet: Znhit1 inhibited inflammatory response in TNC. (a–c) The levels of IL-6 (a), IL-1β (b), and TNF-α (c) were evaluated in TNC tissues using ELISA. (d) The levels of IL-6, IL-1β, TNF-α, COX-2, and iNOS were determined in TNC tissues by western blot assay. One-way analysis of variance followed by Tukey’s post hoc test was utilized to perform statistical analysis, n = 5. COX-2: cyclooxygenase-2; IL-1β: interleukin-1β; IL-6: interleukin-6; iNOS: inducible nitric oxide synthase; TNC: trigeminal nucleus caudalis; TNF-α: tumor necrosis factor-α; Znhit1: zinc finger HIT-type containing 1. ** p < 0.01 versus control group; ## p < 0.01 versus vector group.

Article Snippet: The plasma was used to analyze 5-hydroxytryptamine (5-HT) and CGRP levels using ST/5-HT ELISA Kit (D751013, Sangon) and Mouse Calcitonin Gene Related Peptide (CGRP) ELISA kit (CSB-EQ027706MO, Cusabio).

Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Control, Plasmid Preparation

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Differences in CGRP levels in plasma with and without PI. ( A ) Correlation of α-CGRP levels in PI-plasma and No PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the 95% confidence interval (CI). ( B ) Difference in α-CGRP levels in PI-plasma (represented in green) vs. No PI-plasma (represented in black); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (PI-plasma median = 38.28 pg/mL, No PI-plasma median = 21.26 pg/mL, p ≤ 0.0001). ( C ) Correlation of β-CGRP levels in PI-plasma and No PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Difference in β-CGRP levels in PI-plasma (represented in light blue) vs. No PI-plasma (represented in pink); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (PI-plasma median = 6.909 pg/mL, No PI-plasma median = 6.200 pg/mL, p = ns (non-significant)). **** p < 0.0001.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics, Comparison

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Correlation of α-CGRP and β-CGRP in plasma samples. ( A ) Correlation of α-CGRP levels vs. β-CGRP plasma levels in No PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Correlation of α-CGRP levels vs. β-CGRP levels in PI-plasma. Dark blue line represents the linear regression, and the red dotted line represents the CI.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Comparison of α-CGRP levels in serum and plasma. ( A ) Correlation of α-CGRP serum vs. No PI-plasma levels. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Difference in α-CGRP levels in serum (represented in burgundy) vs. No PI-plasma (represented in black); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (serum median = 24.32 pg/mL, No PI-plasma median = 24.94 pg/mL, p = ns). ( C ) Correlation of α-CGRP serum levels vs. PI-plasma levels. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Difference in α-CGRP levels in serum (represented in burgundy) vs. PI-plasma (represented in green); data are shown as median with CI 95%. Comparison was made using the Wilcoxon Signed-Rank test (serum median = 13.63 pg/mL, PI-plasma median = 38.29 pg/mL, p ≤ 0.01). ** p < 0.010.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Comparison, Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Comparison of β-CGRP levels in serum and plasma. ( A ) Correlation of β-CGRP serum vs. No PI-plasma levels; the dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Difference in β-CGRP concentrations in serum (represented in burgundy) vs. plasma (represented in pink); data are shown as median with CI 95%. Comparisons were made using the Wilcoxon Signed-Rank test (serum median = 3.625 pg/mL, plasma median = 8.516 pg/mL, p ≤ 0.0001). ( C ) Correlation of β-CGRP serum vs. No PI-plasma levels when using PI; the dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Difference in β-CGRP concentrations in serum (represented in burgundy) vs. No PI-plasma with PI (represented in blue); data are shown as median with CI 95%. Comparisons were made using the Wilcoxon Signed-Rank test (serum median = 1.716 pg/mL, plasma with PI median = 6.909 pg/mL, p ≤ 0.0001). **** p < 0.0001.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Comparison, Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Dynamics of CGRP levels along migraine treatment. ( A ) Changes in α-CGRP concentrations in No PI-plasma before starting the treatment (M0), 6 months after starting treatment (M6) ; Wilcoxon Signed-Rank test ( p < 0.01) and ( B ) after 12 months of the beginning of the treatment (M12); Friedman test followed by Dunn’s test. ( C ) Changes in β-CGRP levels in No PI-plasma at M0 and M6 after starting treatment; Wilcoxon Signed-Rank test (ns) and ( D ) M12 Friedman test followed by Dunn’s test. * p < 0.050, ** p < 0.010.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics

Journal: International Journal of Molecular Sciences

Article Title: Plasma with Added Protease Inhibitors Improves Alpha- and Beta-CGRP Measurement Compared to Serum: Towards a Reliable Biomarker for Chronic Migraine

doi: 10.3390/ijms26209958

Figure Lengend Snippet: Analysis of CGRP levels in plasma depending on demographic variables. ( A ) Correlation of α-CGRP No PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( B ) Correlation of α-CGRP PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( C ) Correlation of β-CGRP No PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( D ) Correlation of β-CGRP PI-plasma levels and age. Dark blue line represents the linear regression, and the red dotted line represents the CI. ( E ) Comparison of α-CGRP No PI-plasma levels from patients sorted by sex (column A median = 23.31 pg/mL; column B median = 26.09 pg/mL; p = ns). ( F ) Comparison of α-CGRP PI-plasma levels from patients sorted by sex. ( G ) Comparison of β-CGRP No PI-plasma levels by sex (column A median = 8.350 pg/mL; column B median = 8.849 pg/mL; p = ns). ( H ) Comparison of β-CGRP PI-plasma levels sorted by sex. Data are shown as median with CI 95%. The comparisons in ( E – H ) were made using Mann–Whitney U test.

Article Snippet: α-CGRP and β-CGRP levels in plasma were measured using commercial ELISA tests, using Abbexa CGRP1 (CALCA) ELISA kits for α-CGRP (Abbexa Ltd., Cambridge, UK) [ ] and Cusabio Human Calcitonin Gene Related Peptide ELISA kits for β-CGRP (Cusabio Biotech Co., Wuhan, China) [ ], following the manufacturers’ instructions.

Techniques: Clinical Proteomics, Comparison, MANN-WHITNEY